Parmax Pharma Limited, a active public limited company, was established on 02 November 1994 in Hadamtala, Gujarat, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24231GJ1994PLC023504. Registered under ROC Roc Ahmedabad. it is listed on BSE: 540359. It has an authorized capital of ₹6.00 Cr and a paid-up capital of ₹3.74 Cr.
It upholds a compliant status. In 2024, it reported revenue of ₹11.10 Cr and a net worth of ₹1.05 M. Employing 9 professional, Its leadership includes Ami Shah Rajeshbhai (Director), Nikhil Sureshchandra Uchat (Director), Umang Alkesh Gosalia (Managing Director). Past directors included Prabhudas Devrajbhai Patel, Mansukhbhai Keshavjibhai Jivani, Pramay Amritlal Chhatra. It holds ₹8.40 Cr open charges and ₹14.96 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27,, Hadamtala, Gujarat, 360311.
L24231GJ1994PLC023504
023504
02 November 1994
₹6.00 Cr
₹3.74 Cr
Roc Ahmedabad
Listed (BSE: 540359)
Active
Explore comprehensive insights into Parmax Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ami Shah Rajeshbhai | Director | 17 Jun 2018 | Current |
| Nikhil Sureshchandra Uchat | Director | 25 Apr 2023 | Current |
| Umang Alkesh Gosalia | Managing Director | 02 Jan 2016 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 15 Oct 2011 | Past |
| Pramod Abcsdd | Director | 01 Oct 2010 | Past |
| Pramod Abcsdd | Additional Director | 16 Sep 2016 | Past |
| Pramod Abcsdd | Additional Director | 22 Sep 2018 | Past |
| Pramod Abcsdd | Managing Director | 13 Apr 2021 | Past |
| Pramod Abcsdd | Company Secretary | 25 Jul 2017 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Parmax Pharma Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 28.21% decrease. The company also saw a substantial fall in profitability, with a 5425.72% decrease in profit. The company's net worth observed a substantial decline by a decrease of 98.2%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Parmax Pharma had a promoter holding of 30.83% and a public holding of 69.16%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹84,000,000.00
₹149,618,350.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Apr 2025 | Others | ₹8.40 Cr | Open |
| 31 May 2023 | Others | ₹6.72 Cr | Satisfied |
| 08 Feb 2019 | Hdfc Bank Limited | ₹1.12 Cr | Satisfied |
| 16 Oct 2018 | Hdfc Bank Limited | ₹6.85 Cr | Satisfied |
| 28 Jul 2017 | Hdfc Bank Limited | ₹2.67 M | Satisfied |
Explore comprehensive loan charge details -
Parmax Pharma has a workforce of 9 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Parmax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parmax Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Others amounted to Rs. 8.40 Cr with Charge ID 101092470 was registered on 17 Apr 2025. was recorded as a recent event.
Progress on A charge registered on 31 May 2023 via Charge ID 100775935 with Others was fully satisfied on 07 Apr 2025. was documented.
Progress on Parmax Pharma Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Progress on Parmax Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Ahmedabad. was documented.
Progress on A charge with Others of Rs. 6.72 Cr registered on 31 May 2023 with Charge ID 100775935 was modified on 10 Nov 2023. was documented.
The activity A charge registered on 08 Feb 2019 via Charge ID 100240259 with Hdfc Bank Limited was fully satisfied on 16 Oct 2023. was completed.
Parmax Pharma's quarterly numbers are looking good, with a big increase in sales and profits. EBITDA is also up by a crazy amount. EPS has gone up too. Their stock price has gone up a bit, but it's still down from last year. Overall, things are looking up for Parmax Pharma. #winning #pharmalife.
The CIN of Parmax Pharma Limited is L24231GJ1994PLC023504.
Parmax Pharma Limited is headquartered at Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27,, Hadamtala, Gujarat, 360311.
Parmax Pharma Limited was incorporated on 02 November 1994.
The current directors of Parmax Pharma Limited are
The primary industry of Parmax Pharma Limited is Manufacturing.
Parmax Pharma Limited is listed. It is listed on BSE: 540359.
The authorized capital of Parmax Pharma Limited is ₹6.00 Cr, and the paid-up capital is ₹3.74 Cr.
The compliance status of Parmax Pharma Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX